DiaMedica Therapeutics (DMAC) Interest Expenses (2021 - 2026)

DiaMedica Therapeutics has reported Interest Expenses for 6 years, with the latest figure at $23000.0 in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 2200.0% year-over-year to $23000.0; the trailing twelve-month figure through Mar 2026 stood at $23000.0 (up 2200.0% YoY), and the FY2025 full-year result was $10000.0, down 70.59% from the prior year.
• Interest Expenses for Q1 2026 stood at $23000.0, up from $1000.0 in the prior quarter.
• The five-year high for Interest Expenses was $28.0 million in Q4 2023, with the low at $1000.0 in Q1 2025.
• Historically, Interest Expenses has averaged $10.2 million across 5 years, with a median of $23000.0 in 2026.
• Annual changes were most pronounced in 2025 — Interest Expenses plunged 94.74% — and 2026, when it jumped 2200.0%.
• DiaMedica Therapeutics' Interest Expenses stood at $22.7 million in 2022, then advanced by 23.32% to $28.0 million in 2023, then plunged by 99.93% to $19000.0 in 2024, then tumbled by 94.74% to $1000.0 in 2025, then jumped by 2200.0% to $23000.0 in 2026.
• The last three Interest Expenses figures came in at $23000.0 (Q1 2026), $1000.0 (Q1 2025), and $19000.0 (Q1 2024), per Business Quant data.